Filing Analysis
Neumora Therapeutics, Inc. announced its financial results for the third quarter ended September 30, 2024. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Report date: November 12, 2024
- Reporting period: Third Quarter ended September 30, 2024
- The company is classified as an emerging growth company
- Financial results were furnished via Exhibit 99.1 (Press Release)
Neumora Therapeutics, Inc. announced its financial results for the second quarter ended June 30, 2024. The filing serves as a formal notice of the earnings release issued on August 6, 2024.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2024
- Announcement date: August 6, 2024
- The filing includes Exhibit 99.1 containing the full press release of financial results.
- Company is classified as an 'emerging growth company'.
Neumora Therapeutics, Inc. held its Annual Meeting of Stockholders on June 13, 2024. The meeting resulted in the successful election of two Class I directors and the ratification of Ernst & Young LLP as the company's independent auditor for the fiscal year ending December 31, 2024.
📋 Key Facts
- Annual Meeting held on June 13, 2024.
- Proposal 1: Election of Class I directors Henry O. Gosebruch and Kristina Burow was successful.
- Proposal 2: Ratification of Ernst & Young LLP as independent registered public accounting firm for FY2024 was approved with 102,921,992 votes in favor.
- As of the April 15, 2024 record date, 159,452,584 shares were outstanding and entitled to vote.
Neumora Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2024. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: First Quarter ended March 31, 2024.
- Announcement date: May 7, 2024.
- The company is classified as an emerging growth company.
Neumora Therapeutics announced that the FDA has placed a clinical hold on its Phase 1 trial of NMRA-266, a M4 muscarinic receptor modulator. The hold was triggered by preclinical data showing convulsions in rabbits, though no such side effects have been observed in the approximately 30 human participants dosed to date.
🚩 Red Flags
- Clinical hold by the FDA on a lead/key asset (NMRA-266).
- Safety signal in preclinical models (convulsions in rabbits) directly impacting clinical progress.
- Withdrawal of previous company guidance regarding the drug's development timeline or outlook.
📋 Key Facts
- FDA placed a clinical hold on the Phase 1 trial of NMRA-266 (M4 PAM franchise).
- The decision follows preclinical data showing convulsions in rabbits.
- Phase 1 single ascending dose/multiple ascending dose study is currently paused.
- Approximately 30 participants have been dosed with no observed convulsions in humans.
- Prior guidance regarding NMRA-266 is no longer applicable as of April 15, 2024.
Neumora Therapeutics announced its financial results for the fourth quarter and full year ended December 31, 2023. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: Fourth quarter and full year ended December 31, 2023.
- Announcement date: March 7, 2024.
- The filing includes Exhibit 99.1 containing the full press release of financial results.
Neumora Therapeutics, Inc. filed an 8-K to furnish a corporate presentation intended for use at the 42nd Annual J.P. Morgan Healthcare Conference. The filing is made pursuant to Item 7.01 (Regulation FD Disclosure) and does not contain material non-public information or financial changes.
📋 Key Facts
- The company furnished a corporate presentation dated January 2024 as Exhibit 99.1.
- The presentation is intended for meetings with investors and analysts at the 42nd Annual J.P. Morgan Healthcare Conference.
- The information provided under Item 7.01 is not considered 'filed' for purposes of Section 18 of the Exchange Act or subject to liability under Sections 11 and 12(a)(2) of the Securities Act.